Monoclonal Rat anti‑Mouse MHC Class II I‑A/I‑E Antibody (clone M5/114, Azide‑free,Low Endotoxin, IF, WB) LS‑C812173
Monoclonal Rat anti‑Mouse MHC Class II I‑A/I‑E Antibody (clone M5/114, Azide‑free,Low Endotoxin, IF, WB) LS‑C812173
Antibody:
MHC Class II I-A/I-E Rat anti-Mouse Monoclonal (Azide-free, Low Endotoxin) (M5/114) Antibody
Application:
IF, WB, IP, Flo, Block, Func
Format:
Unconjugated, Azide-free, Low Endotoxin
Overview
Antibody:
MHC Class II I-A/I-E Rat anti-Mouse Monoclonal (Azide-free, Low Endotoxin) (M5/114) Antibody
Application:
IF, WB, IP, Flo, Block, Func
Format:
Unconjugated, Azide-free, Low Endotoxin
Specifications
Description
I-E antibody LS-C812173 is an unconjugated rat monoclonal antibody to mouse I-E (MHC Class II I-A). Validated for Block, Flow, Func, IF, IP and WB.
Target
Mouse MHC Class II I-A/I-E
Reactivity
Mouse
(tested or 100% immunogen sequence identity)
Clonality
IgG2b,k
Monoclonal
Conjugations
Unconjugated
Modifications
Azide-free, Low Endotoxin
Applications
- Immunofluorescence
- Western blot
- Immunoprecipitation
- Flow Cytometry
- Blocking
- Functional Assay
Usage
Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is = 0.25 µg per 10e6/cells in 100 µl volume or 100 µl of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.
Presentation
Sterile solution in PBS, pH 7.2.
Storage
Store at 2°C to 8°C. Do not freeze.
Restrictions
For research use only. Intended for use by laboratory professionals.
Guarantee
This antibody carries the LSBio 100% Guarantee.
LSBio Guarantee
Featured Products
Species:
Mouse
Applications:
IHC, IHC - Paraffin, IHC - Frozen, Western blot, Immunoprecipitation, Flow Cytometry, Functional Assay
Request SDS/MSDS
To request an SDS/MSDS form for this product, please contact our Technical Support department at:
Technical.Support@LSBio.com
Requested From: United States
Date Requested: 2/12/2025